190 related articles for article (PubMed ID: 36998071)
1. CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma.
Thieme E; Bruss N; Sun D; Dominguez EC; Coleman D; Liu T; Roleder C; Martinez M; Garcia-Mansfield K; Ball B; Pirrotte P; Wang L; Xia Z; Danilov AV
Mol Cancer; 2023 Mar; 22(1):64. PubMed ID: 36998071
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
Xie S; Wei F; Sun YM; Gao YL; Pan LL; Tan MJ; Wang SD; Ding J; Chen Y
Haematologica; 2020 Apr; 105(4):1021-1031. PubMed ID: 31289198
[TBL] [Abstract][Full Text] [Related]
5. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.
Brägelmann J; Dammert MA; Dietlein F; Heuckmann JM; Choidas A; Böhm S; Richters A; Basu D; Tischler V; Lorenz C; Habenberger P; Fang Z; Ortiz-Cuaran S; Leenders F; Eickhoff J; Koch U; Getlik M; Termathe M; Sallouh M; Greff Z; Varga Z; Balke-Want H; French CA; Peifer M; Reinhardt HC; Örfi L; Kéri G; Ansén S; Heukamp LC; Büttner R; Rauh D; Klebl BM; Thomas RK; Sos ML
Cell Rep; 2017 Sep; 20(12):2833-2845. PubMed ID: 28930680
[TBL] [Abstract][Full Text] [Related]
6. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription.
Frigault MM; Mithal A; Wong H; Stelte-Ludwig B; Mandava V; Huang X; Birkett J; Johnson AJ; Izumi R; Hamdy A
Cancer Res Commun; 2023 Nov; 3(11):2268-2279. PubMed ID: 37882668
[TBL] [Abstract][Full Text] [Related]
7. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
9. CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism.
Huang WL; Abudureheman T; Xia J; Chu L; Zhou H; Zheng WW; Zhou N; Shi RY; Li MH; Zhu JM; Qing K; Ji C; Liang KW; Guo S; Yin G; Duan CW
Front Cell Dev Biol; 2021; 9():641271. PubMed ID: 33748130
[TBL] [Abstract][Full Text] [Related]
10. Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Gao J; Wang MY; Ren Y; Lwin T; Li T; Yan JC; Sotomayor EM; Duckett DR; Shah BD; Shain KH; Zhao X; Tao J
Haematologica; 2022 May; 107(5):1119-1130. PubMed ID: 34162179
[TBL] [Abstract][Full Text] [Related]
11. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Cidado J; Boiko S; Proia T; Ferguson D; Criscione SW; San Martin M; Pop-Damkov P; Su N; Roamio Franklin VN; Sekhar Reddy Chilamakuri C; D'Santos CS; Shao W; Saeh JC; Koch R; Weinstock DM; Zinda M; Fawell SE; Drew L
Clin Cancer Res; 2020 Feb; 26(4):922-934. PubMed ID: 31699827
[TBL] [Abstract][Full Text] [Related]
12. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
[TBL] [Abstract][Full Text] [Related]
13. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
14. Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma.
Richter GHS; Hensel T; Schmidt O; Saratov V; von Heyking K; Becker-Dettling F; Prexler C; Yen HY; Steiger K; Fulda S; Dirksen U; Weichert W; Wang S; Burdach S; Schäfer BW
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012890
[TBL] [Abstract][Full Text] [Related]
15. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Bisserier M; Wajapeyee N
Blood; 2018 May; 131(19):2125-2137. PubMed ID: 29572378
[TBL] [Abstract][Full Text] [Related]
17. CDK9: a signaling hub for transcriptional control.
Bacon CW; D'Orso I
Transcription; 2019 Apr; 10(2):57-75. PubMed ID: 30227759
[TBL] [Abstract][Full Text] [Related]
18. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H
Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272
[TBL] [Abstract][Full Text] [Related]
19. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis.
Schmitt A; Grimm M; Kreienkamp N; Junge H; Labisch J; Schuhknecht L; Schönfeld C; Görsch E; Tibello A; Menck K; Bleckmann A; Lengerke C; Rosenbauer F; Grau M; Zampieri M; Schulze-Osthoff K; Klener P; Dolnikova A; Lenz G; Hailfinger S
Blood; 2023 Sep; 142(13):1143-1155. PubMed ID: 37294920
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells.
Jiang L; Wen C; Zhou H; Liu A; Zhang H; Chen X; Ding W; Liu J; Shi X
Cancer Biol Ther; 2022 Dec; 23(1):319-327. PubMed ID: 35332847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
